Tysabri Marketing Unaffected By Proposed Risk Management Plan

Marketing of Biogen Idec/Elan's Tysabri would not be restricted by the companies' proposed risk management plan, CDER Office of Medical Policy Director Robert Temple said during a press briefing following an advisory committee meeting on the product's reintroduction